Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Portugal / NCT07475221
Active, not recruiting Observational

Expert Validation of an Autonomous Personalized Physical Activity Algorithm

NCT07475221 · tracked via the Priya Life Science Portugal tracker
Phase
Observational
Started
2026-03-10
Last updated
2026-09-25

Condition(s) studied

Experts in Physical Activity Prescription and Risk Health Screening

Study summary

This study aims to validate a personalized physical activity algorithm for risk screening and individualized exercise prescription using a modified online Delphi process. International experts in physical activity and exercise will evaluate the algorithm's components over two rounds of questionnaires, with consensus defined as ≥70% agreement. If needed, a focus group will resolve any remaining disagreements. Validation of this algorithm may support safer, more effective autonomous exercise, promoting adherence, improved health outcomes, and population-level benefits.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria * Experts in Physical Activity and Exercise with recognized scientific or professional experience and a relevant doctoral degree. * Availability to complete two rounds of the online modified Delphi questionnaire. * Willingness to participate in an online focus group if consensus is not reached. * Ability and willingness to provide informed consent. Exclusion Criteria * Individuals unable to provide informed consent. * Individuals without access to a computer, smartphone, tablet, or other internet-enabled device necessary to complete the online survey.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
School of Health - Polytechnic Institute of Porto Porto Portugal

More Polytechnic Institute of Porto trials in Portugal

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07475221 on ClinicalTrials.gov ↗ ← All trials in Portugal